Video Experimental Relacionado
Updated: Feb 13, 2026
06:46
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
3.4K
Agonistas del receptor GLP-1 y riesgo de ruptura de aneurisma en la diabetes tipo 2: un estudio retrospectivo
Sean Y Li1, Anisha Sonti1, David C Kaelber2
1Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Resumen
Los agonistas de los receptores de péptido-1 similares al glucagón (GLP-1RA) pueden reducir el riesgo de ruptura de aneurisma intracraneal (IA) en pacientes con diabetes tipo 2. Este estudio encontró el uso de GLP-1RA asociado con una menor incidencia de hemorragia subaracnoidea (SAH).
Área de la Ciencia:
- Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular
- Endocrinología Endocrinología.
- La neurocirugía es la neurocirugía.
Sus antecedentes:
- Los aneurismas intracraneales (AI) afectan hasta al 3% de la población, lo que plantea riesgos significativos de morbilidad y mortalidad tras la ruptura.
- Los estudios preclínicos indican que los agonistas de los receptores de péptido-1 similares al glucagón (GLP-1RA) pueden ofrecer beneficios protectores vasculares.
- El papel de las GLP-1RA en la prevención de la ruptura de la IA en grandes cohortes humanas sigue siendo subestimado.
Objetivo del estudio:
- Para investigar la asociación entre el uso de GLP-1RA y el riesgo de ruptura aneurysmal en pacientes con diabetes mellitus tipo 2 (T2DM) y IA sin ruptura.
- Evaluar los potenciales efectos protectores vasculares de las GLP-1RA en el contexto de la gestión del aneurisma intracraneal.
Principales métodos:
- Un estudio de cohorte retrospectivo utilizó la Red de Investigación TriNetX, que incluyó a adultos con DM2T y AIs sin ruptura (2008-2025).
- Los pacientes fueron categorizados en usuarios y no usuarios de GLP-1RA.
- El emparejamiento del puntaje de propensión (PSM) equilibró las cohortes en demografía, comorbilidades y medicamentos; el resultado primario fue la hemorragia subaracnoidea no traumática (SAH) en los seguimientos de 3 y 5 años.
Principales resultados:
- El estudio identificó a 24.776 pacientes con DMT2 con AIs sin ruptura; 3119 eran usuarios de GLP-1RA.
- Después de 1:1 PSM, 2651 pacientes estaban en cada cohorte. Las prescripciones de GLP-1RA se relacionaron con un riesgo significativamente menor de SAH a los 3 años (HR 0.62) y 5 años (HR 0.65).
- No se observaron diferencias significativas en los valores de laboratorio de seguimiento entre los grupos.
Conclusiones:
- Las prescripciones de GLP-1RA en pacientes con DM2T con AIs sin ruptura mostraron una asociación con un riesgo reducido de ruptura aneurysmal.
- Los hallazgos sugieren que las GLP-1RA pueden tener un efecto estabilizador en los aneurismas intracraneales.
- Se necesitan más estudios prospectivos basados en imágenes para confirmar esta asociación y dilucidar los mecanismos subyacentes.
Videos de Conceptos Relacionados
01:22Diabetes Mellitus: Type 2 and Gestational
5.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
01:24Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
01:25Drug-Receptor Interaction: Agonist
4.2K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.2K
01:07Types of Receptors: Internal Receptors
32.7K
Many cellular signals are hydrophilic and cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind intracellular receptors that reside within the cell cytoplasm or nucleus. Many mammalian steroid hormones and nitric oxide (NO) gas use this cell signaling mechanism.
Similar to membrane-bound receptors, the binding of a ligand to the intracellular receptor of causes a conformational change in the...
Similar to membrane-bound receptors, the binding of a ligand to the intracellular receptor of causes a conformational change in the...
32.7K
02:27Predicting Products: SN1 vs. SN2
17.4K
Nucleophilic substitution reactions of alkyl halides can proceed via an SN1 or an SN2 mechanism. While in SN2 reactions, the nucleophile attacks the substrate simultaneously as the leaving group departs, in SN1 reactions, the substrate first dissociates to give the carbocation intermediate. Various factors such as the structure of the substrate, the strength of the nucleophile, and the nature of the solvent promote one mechanism over the other.
With increased substitution on the alkyl halide,...
With increased substitution on the alkyl halide,...
17.4K
01:28Types of Receptors: Cell Surface Receptors
27.6K
Cell-surface receptors, also known as transmembrane receptors, are cell surface, membrane-anchored (integral) proteins that bind to external ligand molecules. This type of receptor spans the plasma membrane and performs signal transduction, converting an extracellular signal into an intracellular signal. Ligands that interact with cell-surface receptors do not have to enter the cell that they affect. Cell-surface receptors are also called cell-specific proteins or markers because they are...
27.6K